Alzheimer's disease drug development pipeline: 2018

Jeffrey Cummings, Garam Lee, Aaron Ritter, Kate Zhong, Jeffrey Cummings, Garam Lee, Aaron Ritter, Kate Zhong

Abstract

Introduction: Treatments for Alzheimer's disease (AD) are needed due to the growing number of individuals with preclinical, prodromal, and dementia forms of AD. Drug development for AD therapies can be examined by inspecting the drug development pipeline as represented on clinicaltrials.gov.

Methods: Clinicaltrials.gov was assessed as of January 30, 2018 to determine AD therapies represented in phase I, phase II, and phase III.

Results: There are 112 agents in the current AD treatment pipeline. There are 26 agents in 35 trials in phase III, 63 agents in 75 trials in phase II, and 23 agents in 25 trials in phase I. A review of the mechanisms of actions of the agents in the pipeline shows that 63% are disease-modifying therapies, 22% are symptomatic cognitive enhancers, and 12% are symptomatic agents addressing neuropsychiatric and behavioral changes. Trials in phase III are larger and longer than phase II or phase I trials, particularly those involving disease-modifying agents. Comparison with the 2017 pipeline shows that there are four new agents in phase III, 14 in phase II, and eight in phase I. Inspection of the use of biomarkers as revealed on clinicaltrials.gov shows that amyloid biomarkers are used as entry criterion in 14 phase III disease-modifying agent trials and 17 disease-modifying agent trials in phase II. Twenty-one trials of disease-modifying agents in phase II did not require biomarker confirmation for AD at trial entry.

Discussion: The AD drug development pipeline is slightly larger in 2018 than in 2017. Trials increasingly include preclinical and prodromal populations. There is an increase in nonamyloid mechanisms of action for drugs in earlier phases of drug development. Biomarkers are increasingly used in AD drug development but are not used uniformly for AD diagnosis confirmation.

Keywords: Alzheimer's; Alzheimer's disease drug development pipeline: 2018; Amyloid; Biomarkers; Clinical trials; Clinicaltrials.gov; Drug development; Monoclonal antibodies; Pipeline; Tau.

Figures

Fig. 1
Fig. 1
Agents in clinical trials for treatment of Alzheimer's disease in 2018 (from clinicaltrials.gov accessed January 30, 2018).
Fig. 2
Fig. 2
Mechanisms of action of agents in phase III.
Fig. 3
Fig. 3
Mechanisms of action of agents in phase II.
Fig. 4
Fig. 4
Site of action of anti-tau agents.

References

    1. Masters C.L., Bateman R., Blennow K., Rowe C.C., Sperling R.A., Cummings J.L. Alzheimer's disease. Nat Rev Dis Primers. 2015;1:15056.
    1. Scheltens P., Blennow K., Breteler M.M., de Strooper B., Frisoni G.B., Salloway S. Alzheimer's disease. Lancet. 2016;388:505–517.
    1. Brookmeyer R., Johnson E., Ziegler-Graham K., Arrighi H.M. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007;3:186–191.
    1. Brookmeyer R., Abdalla N., Kawas C.H., Corrada M.M. Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States. Alzheimers Dement. 2017;14:121–129.
    1. Cummings J.L., Morstorf T., Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6:37–43.
    1. Cummings J., Morstorf T., Lee G. Alzheimer's disease drug development pipeline. Alzheimer's Dement. 2016;2016:222–232.
    1. Cummings J., Lee G., Mortsdorf T., Ritter A., Zhong K. Alzheimer's disease drug development pipeline: 2017. Alzheimer's Dement (N Y) 2017;3:367–384.
    1. Hudson K.L., Lauer M.S., Collins F.S. Toward a new era of trust and transparency in clinical trials. JAMA. 2016;316:1353–1354.
    1. Zarin D.A., Tse T., Williams R.J., Carr S. Trial reporting in - the final rule. N Engl J Med. 2016;375:1998–2004.
    1. Lassman S.M., Shopshear O.M., Jazic I., Ulrich J., Francer J. Clinical trial transparency: a reassessment of industry compliance with clinical trial registration and reporting requirements in the United States. BMJ Open. 2017;7:e015110.
    1. Miller J.E., Wilenzick M., Ritcey N., Ross J.S., Mello M.M. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies. BMJ Open. 2017;7:e017917.
    1. Phillips A.T., Desai N.R., Krumholz H.M., Zou C.X., Miller J.E., Ross J.S. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting. Trials. 2017;18:333–342.
    1. Anderson M.L., Chiswell K., Peterson E.D., Tasneem A., Topping J., Califf R.M. Compliance with results reporting at . N Engl J Med. 2015;372:1031–1039.
    1. Curry S., DeCory H.H., Gabrielsson J., Phase I. The first opportunity for extrapolation from animal data to human exposure. In: Edwards L.D., Fox A.W., Stonier, editors. Principles and Practice of Pharmaceutical Medicine. Wiley-Blackwell; Oxford, UK: 2011. pp. 84–106.
    1. Kelley J. Wiley-Blackwell; Oxford, UK: 2009. Principles of CNS Drug Development: From Test Tube to Patient.
    1. Norfleet E., Gad S.C. Phase I clinical trials. In: Gad C.S., editor. Clinical Trials Handbook. John Wiley & Sons, Inc.; New York, New York: 2009. pp. 245–254.
    1. Atri A., Frolich L., Ballard C., Tariot P.N., Molinuevo J., Boneva N. Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease: 3 randomized clinical trials. JAMA. 2018;319:130–142.
    1. Maher-Edwards G., Dixon R., Hunter J., Gold M., Hopton G., Jacobs G. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. Int J Geriatr Psychiatry. 2011;26:536–544.
    1. Lombardo I. Clinical Trials on Alzheimer's Disease; Boston, MA: 2017. Results from the phase 3 MINDSET STUDY: a global, double-blind, placebo-controlled study of intepirdine in mild-to-moderate Alzheimer's disease.
    1. Wilkinson D., Windfeld K., Colding-Jorgensen E. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2014;13:1092–1099.
    1. Mohler E.G., Baker P.M., Gannon K.S., Jones S.S., Shacham S., Sweeney J.A. The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in rats. Psychopharmacology (Berl) 2012;220:687–696.
    1. Garcia-Osta A., Cuadrado-Tejedor M., Garcia-Barroso C., Oyarzabal J., Franco R. Phosphodiesterases as therapeutic targets for Alzheimer's disease. ACS Chem Neurosci. 2012;3:832–844.
    1. Heckman P.R., Blokland A., Ramaekers J., Prickaerts J. PDE and cognitive processing: beyond the memory domain. Neurobiol Learn Mem. 2015;119:108–122.
    1. Reneerkens O.A., Rutten K., Steinbusch H.W., Blokland A., Prickaerts J. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berl) 2009;202:419–443.
    1. Heckman P.R., Wouters C., Prickaerts J. Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: A translational overview. Curr Pharm Des. 2014;21:317–331.
    1. Prickaerts J., Heckman P.R.A., Blokland A. Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease. Expert Opin Investig Drugs. 2017;26:1033–1048.
    1. Boland K., Moschetti V., Dansirikul C., Pichereau S., Gheyle L., Runge F. A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers. Hum Psychopharmacol. 2017;32:e2569–e2576.
    1. Kleiman R.J., Chapin D.S., Christoffersen C., Freeman J., Fonseca K.R., Geoghegan K.F. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo. J Pharmacol Exp Ther. 2012;341:396–409.
    1. Crowther R.A. Straight and paired helical filaments in Alzheimer disease have a common structural unit. Proc Natl Acad Sci U S A. 1991;88:2288–2292.
    1. Braak H., Braak E. Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl. 1996;165:3–12.
    1. Bakota L., Brandt R. Tau biology and tau-directed therapies for Alzheimer's disease. Drugs. 2016;76:301–313.
    1. Pedersen J.T., Sigurdsson E.M. Tau immunotherapy for Alzheimer's disease. Trends Mol Med. 2015;21:394–402.
    1. Maass A., Landau S., Baker S.L., Horng A., Lockhart S.N., La Joie R. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. Neuroimage. 2017;157:448–463.
    1. Reitz C., Brayne C., Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011;7:137–152.
    1. Morgan P., Brown D.G., Lennard S., Anderton M.J., Barrett J.C., Eriksson U. Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nat Rev Drug Discov. 2018
    1. Hampel H., Lista S., Teipel S.J., Garaci F., Nistico R., Blennow K. Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. Biochem Pharmacol. 2014;88:426–449.
    1. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Jr., Kawas C.H. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263–269.
    1. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270–279.
    1. Dubois B., Feldman H.H., Jacova C., Hampel H., Molinuevo J.L., Blennow K. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–629.
    1. Doody R.S., Farlow M., Aisen P.S. Alzheimer's Disease Cooperative Study Data A, Publication C. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N Engl J Med. 2014;370:1460.
    1. Aisen P., Touchon J., Andrieu S., Boada M., Doody R., Nosheny R.L. Registries and Cohorts to Accelerate Early Phase Alzheimer's Trials. A Report from the E.U./U.S. Clinical Trials in Alzheimer's Disease Task Force. J Prev Alzheimers Dis. 2016;3:68–74.
    1. Zhong K., Cummings J. : from registry to randomization. J Prev Alz Dis. 2016;3:123–126.
    1. Cummings J.L., Aisen P., Barton R., Bork J., Doody R., Dwyer J. Re-engineering Alzheimer clinical trials: Global Alzheimer Platform Network. J Prevent Alz Dis. 2016;3:114–120.
    1. Ritchie C.W., Molinuevo J.L., Truyen L., Satlin A., Van der Geyten S., Lovestone S. Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. Lancet Psychiatry. 2016;3:179–186.
    1. De Angelis C., Drazen J.M., Frizelle F.A., Haug C., Hoey J., Horton R. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med. 2004;351:1250–1251.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren